

# Raymond L Comenzo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5389567/publications.pdf>

Version: 2024-02-01

230  
papers

9,962  
citations

66343

42  
h-index

37204

96  
g-index

233  
all docs

233  
docs citations

233  
times ranked

7056  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Systemic Amyloidoses. <i>New England Journal of Medicine</i> , 1997, 337, 898-909.	27.0	1,135
2	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. <i>Journal of Clinical Oncology</i> , 2012, 30, 4541-4549.	1.6	735
3	Oral Selinexorâ€“Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	27.0	460
4	Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. <i>Blood</i> , 2017, 130, 974-981.	1.4	391
5	Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 4976-4984.	1.6	358
6	Autologous stem cell transplantation for primary systemic amyloidosis. <i>Blood</i> , 2002, 99, 4276-4282.	1.4	335
7	Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. <i>Leukemia</i> , 2012, 26, 2317-2325.	7.2	332
8	Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. <i>Blood</i> , 1998, 91, 3662-3670.	1.4	323
9	Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. <i>Circulation</i> , 2017, 135, 1357-1377.	1.6	319
10	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 46-58.	27.0	268
11	Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. <i>Lancet Oncology</i> , The, 2011, 12, 1195-1203.	10.7	263
12	The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burden. <i>Blood</i> , 2001, 98, 714-720.	1.4	251
13	Deep Venous Thrombosis and Thalidomide Therapy for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2001, 344, 1951-1952.	27.0	213
14	Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. <i>Advances in Therapy</i> , 2015, 32, 920-928.	2.9	187
15	First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. <i>Journal of Clinical Oncology</i> , 2016, 34, 1097-1103.	1.6	176
16	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3741-3749.	1.6	163
17	Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. <i>Blood</i> , 2011, 118, 865-873.	1.4	161
18	Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. <i>Blood</i> , 2009, 114, 1489-1497.	1.4	153

#	ARTICLE	IF	CITATIONS
19	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood And Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
20	Daratumumab plus CyBORd for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. <i>Blood</i> , 2020, 136, 71-80.	1.4	146
21	Pyridone 6, A Pan-Janus Activated Kinase Inhibitor, Induces Growth Inhibition of Multiple Myeloma Cells. <i>Cancer Research</i> , 2006, 66, 9714-9721.	0.9	145
22	Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. <i>Blood</i> , 2006, 107, 3489-3491.	1.4	144
23	A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 4830-4840.	7.0	128
24	Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). <i>Haematologica</i> , 2014, 99, 1479-1485.	3.5	118
25	Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. <i>Blood</i> , 2003, 102, 4369-4376.	1.4	116
26	Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone and thalidomide for systemic light-chain amyloidosis: results of a phase II trial. <i>British Journal of Haematology</i> , 2007, 139, 224-233.	2.5	112
27	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. <i>Blood</i> , 2017, 130, 597-605.	1.4	108
28	Immunoglobulin light chain amyloidosis. <i>Expert Review of Hematology</i> , 2014, 7, 143-156.	2.2	98
29	Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. <i>Journal of Pediatrics</i> , 1992, 120, 926-928.	1.8	88
30	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. <i>The Hematology Journal</i> , 2003, 4, 379-98.	1.4	86
31	Systemic Light-Chain Amyloidosis: Advances in Diagnosis, Prognosis, and Therapy. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 287-294.	2.5	85
32	How I treat amyloidosis. <i>Blood</i> , 2009, 114, 3147-3157.	1.4	80
33	Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation. <i>British Journal of Haematology</i> , 1999, 106, 744-751.	2.5	79
34	Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. <i>British Journal of Haematology</i> , 1999, 104, 553-559.	2.5	68
35	Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. <i>British Journal of Haematology</i> , 2005, 128, 636-644.	2.5	62
36	Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. <i>Blood</i> , 2014, 124, 2498-2506.	1.4	62

#	ARTICLE	IF	CITATIONS
37	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. <i>BMC Family Practice</i> , 2020, 21, 198.	2.9	60
38	Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. <i>British Journal of Haematology</i> , 2003, 122, 728-744.	2.5	59
39	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 10.	6.2	53
40	Frequencies and Types of Arrhythmias in Patients With Systemic Light-Chain Amyloidosis With Cardiac Involvement Undergoing Stem Cell Transplantation on Telemetry Monitoring. <i>American Journal of Cardiology</i> , 2009, 104, 990-994.	1.6	52
41	The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1781-1788.	4.1	52
42	Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis. <i>Blood</i> , 2016, 128, 645-645.	1.4	46
43	Anomalous ABO Phenotype in a Child after an ABO-Incompatible Liver Transplantation. <i>New England Journal of Medicine</i> , 1992, 326, 867-870.	27.0	42
44	Managing Systemic Light-Chain Amyloidosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 179-187.	4.9	41
45	Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. <i>British Journal of Haematology</i> , 2006, 132, 155-161.	2.5	39
46	Meta-Analysis of the Efficacy and Safety of Bortezomib Re-Treatment in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 380-388.	0.4	38
47	CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. <i>Blood</i> , 2008, 111, 3403-3406.	1.4	37
48	Primary systemic amyloidosis. <i>Current Treatment Options in Oncology</i> , 2000, 1, 83-89.	3.0	34
49	One siRNA pool targeting the 5' constant region stops 5' light-chain production and causes terminal endoplasmic reticulum stress. <i>Blood</i> , 2014, 123, 3440-3451.	1.4	34
50	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). <i>Blood</i> , 2019, 134, 139-139.	1.4	34
51	Hematopoietic Cell Transplantation for Primary Systemic Amyloidosis: What Have We Learned. <i>Leukemia and Lymphoma</i> , 2000, 37, 245-258.	1.3	33
52	Plerixafor (Mozobil®) Alone to Mobilize Hematopoietic Stem Cells from Multiple Myeloma Patients for Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 695-700.	2.0	32
53	Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy. <i>Cancer Management and Research</i> , 2020, Volume 12, 7891-7903.	1.9	32
54	Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1455-1462.	1.6	31

#	ARTICLE	IF	CITATIONS
55	AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies. JACC: CardioOncology, 2021, 3, 467-487.	4.0	31
56	Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results Medicare Database. Biology of Blood and Marrow Transplantation, 2015, 21, 1823-1829.	2.0	30
57	A randomized phase 3 study of ixazomib+dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. Leukemia, 2022, 36, 225-235.	7.2	29
58	Clonal Plasma Cell Pathophysiology and Clinical Features of Disease Are Linked to Clonal Plasma Cell Expression of Cyclin D1 in Systemic Light-Chain Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 49-58.	0.4	28
59	Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients. Blood, 2019, 134, 3166-3166.	1.4	27
60	An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma. Blood, 2014, 124, 176-176.	1.4	27
61	CD38 Monoclonal Antibody Therapies for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 635-645.	0.4	25
62	Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan. Blood, 2008, 111, 549-557.	1.4	24
63	Association between spinal stenosis and wild-type ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 226-233.	3.0	23
64	Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination. Blood, 2003, 102, 477-479.	1.4	22
65	Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). Biology of Blood and Marrow Transplantation, 2008, 14, 6-11.	2.0	22
66	The Challenge of Systemic Immunoglobulin Light-Chain Amyloidosis (AL). Sub-Cellular Biochemistry, 2012, 65, 609-642.	2.4	22
67	Clinical and Echocardiographic Correlates of Elevated Troponin in Amyloid Light-Chain Cardiac Amyloidosis. American Journal of Cardiology, 2012, 110, 1180-1184.	1.6	21
68	New Insights and Modern Treatment of AL Amyloidosis. Current Hematologic Malignancy Reports, 2013, 8, 291-298.	2.3	21
69	Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis. Blood, 2016, 127, 2275-2280.	1.4	21
70	Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL). Blood, 2014, 124, 3450-3450.	1.4	21
71	Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e493-e499.	0.4	20
72	Systemic Immunoglobulin Light-Chain Amyloidosis. Clinical Lymphoma and Myeloma, 2006, 7, 182-185.	1.4	19

#	ARTICLE	IF	CITATIONS
73	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.	2.0	19
74	Validation of the Criteria of Response to Treatment In AL Amyloidosis.. <i>Blood</i> , 2010, 116, 1364-1364.	1.4	19
75	Bortezomib Subcutaneous Injection in Combination Regimens for Myeloma or Systemic Light-Chain Amyloidosis: A Retrospective Chart Review of Response Rates and Toxicity in Newly Diagnosed Patients. <i>Clinical Therapeutics</i> , 2013, 35, 1614-1620.	2.5	18
76	Beyond NEOD001 for systemic light-chain amyloidosis. <i>Blood</i> , 2018, 132, 1992-1993.	1.4	18
77	Intraoperative Administration of 4-Factor Prothrombin Complex Concentrate Reduces Blood Requirements in Cardiac Transplantation. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 161-167.	1.3	17
78	High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review. <i>Bone Marrow Transplantation</i> , 2019, 54, 508-518.	2.4	17
79	Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 686-688.	0.4	16
80	Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. <i>Experimental Hematology and Oncology</i> , 2018, 7, 27.	5.0	15
81	Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 184-189.	0.4	15
82	The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types. <i>Blood Reviews</i> , 2021, 45, 100720.	5.7	15
83	Increased thickness of lumbar spine ligamentum flavum in wild-type transthyretin amyloidosis. <i>Journal of Clinical Neuroscience</i> , 2021, 84, 33-37.	1.5	15
84	A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. <i>Blood</i> , 2014, 124, 4741-4741.	1.4	15
85	Out, Out â€” Making Amyloidâ€™s Candle Briefer. <i>New England Journal of Medicine</i> , 2015, 373, 1167-1169.	27.0	14
86	Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. <i>Blood</i> , 2010, 116, 41-41.	1.4	14
87	Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with International Staging System stage II or III, or extramedullary disease. <i>Leukemia and Lymphoma</i> , 2012, 53, 275-281.	1.3	13
88	Three-dimensional Speckle Tracking Echocardiography in Light Chain Cardiac Amyloidosis: Examination of Left and Right Ventricular Myocardial Mechanics Parameters. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2015, 68, 657-664.	0.6	13
89	Myelopathy from WaldenstrÃ¶m's macroglobulinemia: improvement after Rituximab therapy. <i>Journal of Neuro-Oncology</i> , 2003, 63, 207-211.	2.9	12
90	Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 156-159.	3.0	12

#	ARTICLE	IF	CITATIONS
91	Use of novel therapies in the treatment of light chain amyloidosis. <i>Blood Reviews</i> , 2019, 37, 100581.	5.7	12
92	Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e137-e143.	0.4	12
93	A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma. <i>Blood</i> , 2012, 120, 4029-4029.	1.4	12
94	MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study. <i>Blood</i> , 2012, 120, 731-731.	1.4	12
95	Primary Amyloidosis With Renal Involvement: Outcomes in 77 Consecutive Patients at a Single Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 759-766.	0.4	11
96	Wild-Type Transthyretin Amyloidosis Occurring in the Ligamentum Flavum of the Cervicothoracic Spine. <i>World Neurosurgery</i> , 2020, 142, e325-e330.	1.3	11
97	Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. <i>Blood</i> , 2020, 136, 48-50.	1.4	11
98	Interim Analysis of a Randomized Phase II Trial Comparing Continuous Lenalidomide and Dexamethasone to Autologous Stem Cell Transplantation in Multiple Myeloma Patients Responsive to Lenalidomide and Dexamethasone Induction. <i>Blood</i> , 2014, 124, 3991-3991.	1.4	11
99	A glycosaminoglycan inhibitor of thrombin: A new mechanism for abnormal hemostatic assays in cancer. <i>American Journal of Hematology</i> , 1991, 38, 24-29.	4.1	10
100	Where Neurosurgery Meets Heart Failure: A Case Report of a Patient with Amyloid Transthyretin Wild Type in the Ligamentum Flavum and Cardiac Tissue with Bilateral Carpal Tunnel Syndrome. <i>World Neurosurgery</i> , 2019, 131, 104-107.	1.3	10
101	Presence of soluble and cell surface cell maturation antigen in systemic light chain amyloidosis and its modulation by gamma secretase inhibition. <i>American Journal of Hematology</i> , 2020, 95, E110-E113.	4.1	10
102	Lumbar ligamentum flavum burden: Evaluating the role of ATTRwt amyloid deposition in ligamentum flavum thickness at all lumbar levels. <i>Clinical Neurology and Neurosurgery</i> , 2021, 206, 106708.	1.4	10
103	AL amyloidosis and progression to multiple myeloma with gain(1q). <i>British Journal of Haematology</i> , 2009, 144, 963-964.	2.5	9
104	LECT2 makes the amyloid list. <i>Blood</i> , 2014, 123, 1436-1437.	1.4	9
105	Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ3 receptor 3A V158F polymorphisms. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 101-102.	3.0	9
106	NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction: Results from the Expansion Cohort of a Phase 1/2 Study. <i>Blood</i> , 2016, 128, 644-644.	1.4	9
107	Plasma Cell Neoplasms, Their Precursor States, and Their Prediction of Organ Damage. <i>Journal of Clinical Oncology</i> , 2014, 32, 2679-2682.	1.6	8
108	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2020, 191, 442-452.	2.5	8

#	ARTICLE	IF	CITATIONS
109	In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels <math>\leq 10\text{mg/L}</math> Are Associated with Optimal Long-Term Survival. <i>Blood</i> , 2019, 134, 4369-4369.	1.4	8
110	Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy. <i>Annals of Hematology</i> , 2022, 101, 369-378.	1.8	8
111	How we treat systemic light-chain amyloidosis. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 315-24.	0.3	8
112	Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2000, 7, 126-132.	3.0	7
113	A novel xenograft mouse model for testing approaches targeting human kappa light-chain diseases. <i>Gene Therapy</i> , 2019, 26, 187-197.	4.5	7
114	Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 656-669.	2.0	7
115	Advances in the Treatment of Plasma Cell Diseases. <i>Hospital Practice (1995)</i> , 1996, 31, 67-88.	1.0	6
116	A Case of T-Cell Large Granular Lymphocytic Leukemia and Renal Immunoglobulin Heavy Chain Amyloidosis. <i>American Journal of Case Reports</i> , 2019, 20, 43-47.	0.8	6
117	Prompt engraftment using autologous peripheral blood stem cells for double autologous bone marrow rescue. <i>American Journal of Hematology</i> , 1991, 36, 152-153.	4.1	5
118	How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e826-e831.	0.4	5
119	B-Cell Maturation Antigen (BCMA) in Systemic Light-Chain Amyloidosis (AL): Association with Disease Activity and Its Modulation with Gamma-Secretase Inhibition. <i>Blood</i> , 2019, 134, 4409-4409.	1.4	5
120	Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. <i>Blood</i> , 2020, 136, 44-45.	1.4	5
121	Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda. <i>Blood</i> , 2020, 136, 6-7.	1.4	5
122	Subcutaneous Bortezomib in Combination Regimens in Newly Diagnosed Patients with Myeloma or Systemic AL Amyloidosis: High Response Rates and Minimal Toxicity.. <i>Blood</i> , 2012, 120, 2968-2968.	1.4	5
123	Long-Term Outcomes of Patients with Systemic Light Chain Amyloidosis (AL) Treated At Diagnosis with Risk-Adapted Stem Cell Transplant and Consolidation with Novel Agents.. <i>Blood</i> , 2012, 120, 3150-3150.	1.4	5
124	Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light Chain (AL) Amyloidosis. <i>Blood</i> , 2014, 124, 3480-3480.	1.4	5
125	The VITAL Amyloidosis Study: A Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study of NEOD001 in Patients with AL Amyloidosis and Cardiac Dysfunction. <i>Blood</i> , 2016, 128, 5690-5690.	1.4	5
126	Plasma Cell Gene-Expression Profiles in Patients with Systemic AL Amyloidosis: Responses to Melphalan and Stem Cell Transplant Are Associated with Differential Expression of Genes Involved in Translation, Protein Degradation and Detoxification.. <i>Blood</i> , 2005, 106, 3405-3405.	1.4	5



#	ARTICLE	IF	CITATIONS
127	Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study. <i>Blood</i> , 2021, 138, 159-159.	1.4	5
128	Twists and turns of determining amyloid type and amyloid-related organ damage: discordance and clinical skepticism in the era of proteomic typing. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 62-65.	3.0	4
129	Preliminary evidence of efficacy of venetoclax in relapsed and refractory AL amyloidosis.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e327-e328.	0.4	4
130	Liver and Gastrointestinal Involvement. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 1081-1090.	2.2	4
131	Implementation and impact of a multidisciplinary coagulation factor stewardship program at an academic medical center. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 715-717.	2.1	4
132	Involved free light chains <math>\geq 10\text{ mg/L}</math> with treatment predict better outcomes in systemic light-chain amyloidosis. <i>American Journal of Hematology</i> , 2021, 96, E20-E23.	4.1	4
133	Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 701-710.	0.4	4
134	Seeking AL Amyloidosis Very Early: The SAVE Trial – Identifying Clonal Lambda Light Chain Genes in Patients with MGUS or Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 1903-1903.	1.4	4
135	Adjuvant Bortezomib and Dexamethasone Following Risk-Adapted Melphalan and Stem Cell Transplant in Systemic Light-Chain Amyloidosis (AL): A Phase II Study.. <i>Blood</i> , 2009, 114, 533-533.	1.4	4
136	Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy. <i>Blood</i> , 2010, 116, 2391-2391.	1.4	4
137	Splenic Irradiation and a Reduced-Intensity Conditioning Regimen Prior to Allogeneic Stem-Cell Transplantation for Myelofibrosis. <i>Blood</i> , 2014, 124, 3170-3170.	1.4	4
138	A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, yttrium-90) T <sub>j</sub> ETQq0 0 0 rgBT /Overlock 10 Tf 50 312 Stem Cell Transplant (ASCT) for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S199.	2.0	3
139	Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare. <i>Bone Marrow Research</i> , 2016, 2016, 1-6.	1.7	3
140	Adjuvant Dexamethasone (D) ± Thalidomide (T) Improves Hematologic and Organ Responses after Risk-Adapted High-Dose Melphalan with Autologous Stem Cell Transplant (SCT) for Patients with Systemic AL Amyloidosis (AL).. <i>Blood</i> , 2005, 106, 1163-1163.	1.4	3
141	Coincidental Gammopathies In Patients with Systemic Amyloidosis and Transthyretin Gene Mutations. <i>Blood</i> , 2010, 116, 2948-2948.	1.4	3
142	Belantamab Mafadotin in Patients with Relapsed/Refractory AL Amyloidosis with Myeloma. <i>Blood</i> , 2021, 138, 1670-1670.	1.4	3
143	Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study. <i>Blood</i> , 2020, 136, 11-11.	1.4	3
144	Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study. <i>American Journal of Hematology</i> , 2022, 97, 719-730.	4.1	3

#	ARTICLE	IF	CITATIONS
145	Immunotherapy in AL Amyloidosis. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1059-1071.	3.0	3
146	Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 113-114.	3.0	2
147	Smoldering multiple myeloma – Past, present, and future. <i>Blood Reviews</i> , 2021, , 100869.	5.7	2
148	Increased Calreticulin Expression in Clonal Plasma Cells Is Associated with Complete Response to Melphalan and Autologous Stem Cell Transplant in Systemic Light-Chain Amyloidosis.. <i>Blood</i> , 2006, 108, 3096-3096.	1.4	2
149	Early Adjuvant Treatment after Risk-Adapted Autologous Stem Cell Transplant for Systemic Light-Chain Amyloidosis: Increased Hospitalizations and Impaired Immune Recovery but Improved Responses and Overall Survival.. <i>Blood</i> , 2008, 112, 3329-3329.	1.4	2
150	Urinary Excretion of Epinephrine and Dopamine Correlates with Efficiency of G-CSF Mobilized Stem Cells in Patients with AL Amyloidosis. <i>Blood</i> , 2011, 118, 316-316.	1.4	2
151	Risk-Adapted Melphalan and Stem Cell Transplant for Systemic Light Chain Amyloidosis: A Single Institution Experience.. <i>Blood</i> , 2012, 120, 3109-3109.	1.4	2
152	Updated Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. <i>Blood</i> , 2015, 126, 3041-3041.	1.4	2
153	Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma.. <i>Blood</i> , 2004, 104, 2409-2409.	1.4	2
154	Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response. <i>Blood</i> , 2008, 112, 3712-3712.	1.4	2
155	The PRONTO amyloidosis study: A randomized, double-blind, placebo-controlled, global, phase 2b study of NEOD001 in previously treated subjects with light chain amyloidosis and persistent cardiac dysfunction.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8073-TPS8073.	1.6	2
156	Effective Lipidoid Nanoparticle Delivery In Vivo of siRNA Targeting Kappa Light Chain Production in a Murine Xenograft Model. <i>Blood</i> , 2018, 132, 3208-3208.	1.4	2
157	OAB-034: Evaluating the impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis: subanalyses from the ANDROMEDA study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S22.	0.4	2
158	Unraveling a rare cause of spinal stenosis: Coexistent AL and ATTR amyloidosis involving the ligamentum flavum. , 2022, 13, 12.		2
159	A case report – renal heavy chain amyloidosis and T-cell large granular lymphocytic leukaemia. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 130-131.	3.0	1
160	Stigmata of amyloidosis; external manifestations of internal disease. <i>British Journal of Haematology</i> , 2019, 186, 10-10.	2.5	1
161	Therapeutic Activity of Combining BCL-2 and HMG-CoA Reductase Inhibition in Systemic Light-Chain Amyloidosis. <i>Blood</i> , 2020, 136, 23-24.	1.4	1
162	The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.. <i>Blood</i> , 2005, 106, 3481-3481.	1.4	1

#	ARTICLE	IF	CITATIONS
163	Predictors of Survival in De Novo Cardiac Amyloidosis.. Blood, 2007, 110, 2870-2870.	1.4	1
164	The Majority of Patients with Relapsing Light Chain (AL) Amyloidosis Are Not Eligible for Enrollment Onto Clinical Trials: Using Screen Failures to Define Major Unmet Medical Needs. Blood, 2015, 126, 1786-1786.	1.4	1
165	Impact of Cardiac Stage and Hematologic Response on AL Amyloidosis Patients with Renal Involvement. Blood, 2016, 128, 2136-2136.	1.4	1
166	Final Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone in Patients with Previously Treated Systemic Light-Chain (AL) Amyloidosis. Blood, 2016, 128, 4523-4523.	1.4	1
167	Risk-Adapted Melphalan and Stem Cell Transplantation after Suboptimal Responses to Bortezomib-Based Initial Therapy in Patients with Systemic Light-Chain Amyloidosis (AL). Blood, 2016, 128, 5831-5831.	1.4	1
168	Organ Biomarker Responses in Patients with Light Chain Amyloidosis Treated with NEOD001 Are Independent of Previous Hematologic Response. Blood, 2016, 128, 647-647.	1.4	1
169	Elevated Cyclin D1 (CCND1) Expression in the Plasma Cells of Patients with Systemic AL Amyloidosis at Diagnosis Is Associated with Higher Brain Natriuretic Peptide (BNP) Levels, Increased Plasma Cells and Significantly Poorer Survival.. Blood, 2009, 114, 2815-2815.	1.4	1
170	Weekly Combination Chemotherapy with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for Newly Diagnosed Patients with Advanced Cardiac Disease Due to Systemic AL Amyloidosis. Blood, 2011, 118, 5139-5139.	1.4	1
171	Meta-Analysis of the Efficacy and Safety of Bortezomib Retreatment in Patients with Multiple Myeloma (MM). Blood, 2012, 120, 1863-1863.	1.4	1
172	siRNA for the Ig Light Chain Constant Region Reduces Light Chain Production and Secretion By Human Plasma Cells and in a Murine Xenograft Model. Blood, 2014, 124, 5722-5722.	1.4	1
173	Senescent CD8+ T Cells in Myeloma Patients: Implications for Cellular Therapies. Blood, 2018, 132, 5688-5688.	1.4	1
174	Clinical correlation of positive direct antiglobulin tests in patients with sickle cell disease. Immunohematology, 1992, 8, 13-16.	0.2	1
175	Risk Factors for Early Sudden Cardiac Death in Patients with Systemic Light-Chain Amyloidosis on Treatment. Blood, 2021, 138, 3756-3756.	1.4	1
176	Pattern of Use and Efficacy of Daratumumab-Based Therapy in Patients with AL Amyloidosis: A Single Institution Experience. Blood, 2020, 136, 44-45.	1.4	1
177	Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience. Leukemia and Lymphoma, 2022, , 1-5.	1.3	1
178	Who knows how to treat systemic light chain amyloidosis?. Oncology, 2011, 25, 626, 628-9, 632-3.	0.5	1
179	Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. Leukemia and Lymphoma, 0, , 1-10.	1.3	1
180	Risk-Adapted Melphalan and Stem Cell Transplant for Systemic Light Chain Amyloidosis: A Single Institution Experience. Biology of Blood and Marrow Transplantation, 2013, 19, S131-S132.	2.0	0

#	ARTICLE	IF	CITATIONS
181	Improvement of Blood Glucose Control on the Bone Marrow Transplant (BMT) Unit: A Retrospective Review of Our Quality Improvement Pilot Program. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S202.	2.0	0
182	Extracorporeal Photophoresis in Reduced Intensity Conditioning: 14 Year Follow-up of 206 Patients Reveals an Efficacious Regimen with Low Rates of GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S35-S36.	2.0	0
183	SP051NEOD001 DEMONSTRATES RENAL BIOMARKER RESPONSES IN A PHASE 1/2 STUDY IN PATIENTS WITH IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT RENAL DYSFUNCTION. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i103-i103.	0.7	0
184	NEOD001 Demonstrates Cardiac Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction in a Phase 1/2 Study Expansion. <i>Journal of Cardiac Failure</i> , 2016, 22, S64.	1.7	0
185	Toxicities, response and survival: Autologous stem cell transplantation for multiple myeloma over 25 years at a single center. <i>Cancer Treatment and Research Communications</i> , 2017, 11, 1-5.	1.7	0
186	NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 825.	2.8	0
187	Organ Biomarker Responses in Patients With Light Chain Amyloidosis Treated With NEOD001 Are Independent of Previous Hematologic Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e97-e98.	0.4	0
188	Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission But With Persistent Renal Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e335-e336.	0.4	0
189	Shedding Tears to Clear the Way. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, xiii-xiv.	2.2	0
190	Febrile Neutropenia and Bacteremia after High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients Treated Inpatient Versus Outpatient. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S47-S48.	2.0	0
191	Implementing structured handoffs to verify operating room blood delivery using a quality academy training program: an interrupted time-series analysis. <i>International Journal for Quality in Health Care</i> , 2021, 33, .	1.8	0
192	OUP accepted manuscript. <i>Clinical Chemistry</i> , 2021, 67, 1588-1589.	3.2	0
193	Frequency of Molecular and PET/CT Complete Remissions in Patients with Multiple Myeloma after Autologous Followed by Reduced-Intensity Allogeneic Stem Cell Transplants.. <i>Blood</i> , 2004, 104, 5113-5113.	1.4	0
194	Risk-Adapted Intravenous Melphalan Followed by Adjuvant Dexamethasone (D) and Thalidomide (T) for Newly Diagnosed Patients with Systemic AL Amyloidosis (AL): Interim Results of a Phase II Study.. <i>Blood</i> , 2004, 104, 542-542.	1.4	0
195	Risk-Adapted Dosing of Melphalan for Systemic AL Amyloidosis (AL) Lowers Treatment-Related Mortality: Early Death but Not Post-3 Month Survival Is Linked to Cardiac Involvement.. <i>Blood</i> , 2005, 106, 1156-1156.	1.4	0
196	The Abdominal Fat Pad Aspirate for Diagnosing Amyloidosis Is a Useful Tool.. <i>Blood</i> , 2005, 106, 5107-5107.	1.4	0
197	Seeking Diagnostic Confidence in Typing Amyloidosis: Prospective Results with an Algorithm To Minimize Misdiagnosis of Immunoglobulin Light-Chain (AL) Amyloidosis.. <i>Blood</i> , 2005, 106, 5099-5099.	1.4	0
198	Single Agent AMD3100 Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation in Patients with Multiple Myeloma (MM).. <i>Blood</i> , 2006, 108, 3381-3381.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Mobilization of Blood Stem Cells with G-CSF in Systemic Light-Chain Amyloidosis: Dominant Organ Involvement Significantly Affects Stem Cell Collection.. Blood, 2006, 108, 3087-3087.	1.4	0
200	CD32B on Clonal Plasma Cells in Systemic Light-Chain Amyloidosis (AL) and Multiple Myeloma (MM): A Target for Immunotherapy in Both Disorders and a Prognostic Marker in MM.. Blood, 2006, 108, 3489-3489.	1.4	0
201	High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.. Blood, 2007, 110, 5113-5113.	1.4	0
202	MAGE-A3 or NY-ESO1 Expression and Spontaneous Antibody Responses to NY-ESO1 in Newly Diagnosed Multiple Myeloma Patients Are Associated with Worse Overall Survival. Blood, 2008, 112, 5110-5110.	1.4	0
203	CD32B Expression Reflects Phenotypic and Functional Heterogeneity in Multiple Myeloma (MM). Blood, 2008, 112, 842-842.	1.4	0
204	Outcome of Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation in the Era of Novel Therapies.. Blood, 2009, 114, 1865-1865.	1.4	0
205	Cancer-Testis (CT) Antigen Expression In AL Amyloidosis. Blood, 2010, 116, 4055-4055.	1.4	0
206	Cyclin D1 Overexpression In Clonal Plasma Cells In Systemic AL Amyloidosis Is Associated with Differential Expression of Protein Quality Control Genes and Bias In Clonal Germline IgVL donor Gene Use. Blood, 2010, 116, 4043-4043.	1.4	0
207	Allogeneic NK Cell Therapy After Autologous Stem Cell Transplant: Results of a Phase I Study. Blood, 2010, 116, 4299-4299.	1.4	0
208	Outcomes Following Salvage Autologous Stem Cell Transplant for Multiple Myeloma. Blood, 2010, 116, 1353-1353.	1.4	0
209	Proteasome Activity As a Biomarker in Multiple Myeloma (MM): In MM Cells Treated with Bortezomib (BTZ) or Epoxomicin (EPX) Caspase 3/7 Activation Is Inversely Related to Baseline $\beta$ 21 and $\beta$ 25 Activity. Blood, 2011, 118, 1431-1431.	1.4	0
210	Proteasome Activity Not M-Protein Production Influences Multiple Myeloma (MM) Responsiveness to Bortezomib (BZB): The Key Role of PSMB5,. Blood, 2011, 118, 3491-3491.	1.4	0
211	Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Patients $\geq$ 60 Years of Age with a Novel Reduced Intensity Conditioning Regimen Incorporating Extracorporeal Photopheresis,. Blood, 2011, 118, 4153-4153.	1.4	0
212	Results after long-term follow-up from the CAN2007 phase I/II study of weekly or twice-weekly bortezomib in patients (pts) with relapsed systemic light-chain (AL) amyloidosis.. Journal of Clinical Oncology, 2013, 31, 8545-8545.	1.6	0
213	Plerixafor and G-CSF For Autologous Stem Cell Mobilization In AL Amyloidosis: A Single Center Experience. Blood, 2013, 122, 4516-4516.	1.4	0
214	Photopheresis As Part of Conditioning Reduces Incidence of Severe Graft Versus Host Disease: Fourteen Year Follow-up of a Novel Reduced Intensity Regimen for Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 5924-5924.	1.4	0
215	Increased Bone Marrow Plasma Cells at Diagnosis Predicts Overall Mortality in AL Amyloidosis Patients Undergoing Risk-Adapted Stem Cell Transplant. Blood, 2014, 124, 2522-2522.	1.4	0
216	Hepatitis B (HBV) Screening in Patients Receiving Rituximab: A Comprehensive Analysis Including Comparison of Adherence By Oncologists and Non-Oncologists. Blood, 2014, 124, 2595-2595.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials. <i>Blood</i> , 2015, 126, 1975-1975.	1.4	0
218	The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis. <i>Blood</i> , 2015, 126, 3049-3049.	1.4	0
219	Colchicine Can be an Effective Adjunctive Treatment for Extensive Refractory Chronic-Graft-Versus-Host Disease. <i>Blood</i> , 2015, 126, 5461-5461.	1.4	0
220	Improvements in Patient Outcomes with Autologous Stem Cell Transplantation for Multiple Myeloma over 25 Years at a Single Center. <i>Blood</i> , 2015, 126, 5496-5496.	1.4	0
221	Identifying a Murine Xenograft Model Relevant to Light-Chain Specific Approaches to Human Ig Light-Chain Diseases. <i>Blood</i> , 2018, 132, 5611-5611.	1.4	0
222	Monoclonal Gammopathies and Their Significance: A Retrospective Analysis of Monoclonal Gammopathy and Renal Disease. <i>Blood</i> , 2019, 134, 5498-5498.	1.4	0
223	Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission but with Persistent Renal Disease. <i>Blood</i> , 2019, 134, 5500-5500.	1.4	0
224	Another Obesity Paradox: In Cardiac AL Amyloid a Higher BMI Is Associated with a Lower Rate of Cardiac Response. <i>Blood</i> , 2019, 134, 5502-5502.	1.4	0
225	The Pattern of Organ Responses Varies in Patients with Systemic Light-Chain Amyloidosis and Heart or Kidney or Heart and Kidney Involvement Who Achieve Deep Hematologic Responses. <i>Blood</i> , 2021, 138, 2715-2715.	1.4	0
226	Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial. <i>Blood</i> , 2021, 138, 4771-4771.	1.4	0
227	Outcomes of Patients with Multiple Myeloma Harboring Gain/Amplification 1q in the Era of Modern Therapy. <i>Blood</i> , 2020, 136, 45-46.	1.4	0
228	Pattern of Use and Outcomes of Daratumumab Therapy in Patients with Multiple Myeloma in a Real-World Setting: A Single Institution Experience. <i>Blood</i> , 2020, 136, 16-17.	1.4	0
229	Autologous Hematopoietic Cell Transplantation for Systemic Light Chain (AL-) Amyloidosis. , 0, , 914-930.		0
230	Laboratory-Based Rationale for Targeting the Protein Homeostasis Network in AL Amyloidosis. <i>Hemato</i> , 2022, 3, 298-317.	0.6	0